Regeneron (REGN) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
February 11, 2015 8:54 AM ESTRoth Capital affirms Regeneron (Nasdaq: REGN) at Buy with a price target of $461 following Q4, FY14 results reported earlier in the week.
Analyst Joseph Pantginis noted that Q4 GAAP EPS of $0.96 compared with his estimate of $1.36. The analyst attributed the miss to continued pipeline expansion as well as growing R&D reimbursement payments to Bayer and Sanofi."
Following results, Pantginis commented, We... More
Piper Jaffray Downgrades Regeneron Pharma (REGN) to Neutral
February 10, 2015 10:54 AM ESTPiper Jaffray downgraded Regeneron Pharma (NASDAQ: REGN) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $399.72 yesterday.
... More